AstraZeneca has entered an exclusive licence agreement with Alteogen involving the latter’s ALT-B4 platform technology.

Latigo has secured $150m in a Series funding round, which will be used to further the development of its Nav1.8 inhibitors.

Experts at the 2025 Clinical Trial Supply New England conference will discuss strategies for optimising clinical supply ...

The two simultaneous Incyte trials in HS saw more than 40% of patients on povorcitinib achieving a clinical response.

Azurity Pharmaceuticals has acquired Covis Group from existing investors, making the latter a wholly owned subsidiary.

Taiho Pharmaceutical has agreed to acquire Swiss-based antibody-drug-conjugate (ADC) specialist Araris Biotech for up to ...

While China has become a key country for global clinical trials, navigating regulatory complexities and ensuring data ...

The EC has granted expanded approval to BMS' Breyanzi, to treat adults with relapsed or refractory follicular lymphoma (FL).

Telix states its automated and high-throughput generator can produce sufficient lead-212 elution for up to 60 clinical doses, ...

WuXi XDC Cayman has signed a memorandum of understanding (MoU) with South Korea-based AbTis to advance next-generation ADCs.

The deal comes after a challenging few years for 2seventy bio, which had divested research programmes in recent years.

Roche has announced the launch of the Roche Genentech Innovation Center Boston, which will serve as the company’s CVRM hub.